흑색종 치료제 시장 보고서(2026년)

Melanoma therapeutics refer to treatment approaches used for managing melanoma, a type of skin cancer that arises from melanocytes. These therapies act by targeting abnormal cells, either by destroying them directly or by inhibiting their growth and multiplication.

The main types of melanoma therapeutic drugs include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are laboratory-produced therapeutic proteins that can bind to specific targets, such as antigens found on cancer cells. Treatment approaches include surgery, radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and are administered through various routes including oral and injectable forms. The cancer types treated include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others, which are diagnosed using methods such as dermatoscopy, sentinel lymph node biopsy, blood tests, X-ray, ultrasound, and CT scans.

Tariffs have influenced the melanoma therapeutics market by increasing the cost of imported biologics, monoclonal antibodies, and small molecule inhibitors, which has affected the overall affordability of treatments. The impact is most pronounced in segments like monoclonal antibodies and targeted therapies, and in regions heavily reliant on imports such as North America and Europe. While tariffs create cost pressures, they also encourage local manufacturing and domestic production of therapies, potentially fostering innovation and reducing supply chain dependency over time.

The melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides melanoma therapeutics market statistics, including melanoma therapeutics industry global market size, regional shares, competitors with a melanoma therapeutics market share, detailed melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma therapeutics industry. This melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma therapeutics market size has grown rapidly in recent years. It will grow from $4.47 billion in 2025 to $4.94 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising melanoma incidence, development of monoclonal antibodies, increased awareness of skin cancer, advancements in radiation therapy, adoption of dermatoscopy,.

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $7.49 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to growth in precision medicine, expansion of immunotherapy treatments, innovations in small molecule inhibitors, increasing healthcare expenditure, rising adoption of AI in diagnostics. Major trends in the forecast period include personalized melanoma therapy development, immunotherapy adoption growth, targeted therapy innovation, advanced diagnostic techniques integration, combination treatment strategies.

The increasing incidence of melanoma is expected to drive the growth of the melanoma therapeutics market in the coming years. Melanoma is a form of skin cancer that originates in melanocytes, the cells responsible for skin pigmentation. Melanoma therapeutics include a range of treatments and drugs used to manage and treat patients with melanoma by targeting cancer cells and reducing disease progression. As the incidence of melanoma continues to rise, the demand for effective therapeutic options increases, thereby boosting sales in the melanoma therapeutics market. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, Australia is projected to record approximately 209,000 new cancer diagnoses by 2034, a substantial increase from the estimated 169,000 cases expected in 2024, reflecting population growth and rising cancer rates. In addition, cancer is expected to account for nearly three out of every ten deaths in Australia in 2024. Therefore, the rising incidence of melanoma is contributing to the growth of the melanoma therapeutics market.

Companies operating in the melanoma therapeutics market are concentrating on innovative developments such as subcutaneous immunotherapy formulations to improve treatment convenience and enhance patient adherence. Subcutaneous immunotherapy formulations are injectable cancer treatments designed to deliver immune-modulating agents beneath the skin, offering efficacy comparable to intravenous administration while reducing treatment time and procedural complexity. For example, in December 2024, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration for Opdivo Qvantig, a subcutaneous co-formulation of nivolumab and hyaluronidase. This formulation demonstrated non-inferior pharmacokinetics, comparable safety, and similar overall response rates to the intravenous version in the Phase 3 CheckMate-67T trial. The approval marked the introduction of the first subcutaneously administered PD-1 inhibitor, enabling faster administration and greater treatment flexibility for patients with solid tumors, including melanoma.

In October 2023, Bristol Myers Squibb acquired Mirati Therapeutics for approximately $4.8 billion. Through this acquisition, the company aims to strengthen and diversify its oncology portfolio by adding next-generation targeted therapies and expanding its presence in cancers driven by KRAS mutations. Mirati Therapeutics is a US-based developer of targeted oncology medicines and clinical-stage therapies focused on genetic and immunologic drivers of cancer.

Major companies operating in the melanoma therapeutics market are AstraZeneca plc, Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, Oncolys BioPharma Inc., Iovance Biotherapeutics Inc., Eisai Co. Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics Inc., Infinity Pharmaceuticals Inc., Spring Bank Pharmaceuticals Inc., AIM ImmunoTech Inc.

North America was the largest region in the melanoma therapeutics market in 2025. The regions covered in the melanoma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The melanoma therapeutics market includes revenues earned by entities by providing stereotactic radiosurgery, stereotactic ablative radiation therapy, intralesional therapy, and palliative therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Melanoma Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for melanoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The melanoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibodies; Small Molecule Inhibitors; Other Drug Types
• 2) By Therapy: Surgery; Radiation Therapy; Immunotherapy; Targeted Therapy; Chemotherapy
• 3) By Route of administration: Oral; Injectable
• 4) By Cancer Type: Superficial Spreading Melanoma; Nodular Melanoma; Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Amelanotic Melanoma; Other Cancer Types
• 5) By Diagnosis: Dermatoscopy; Sentinel Lymph Node Biopsy; Blood Test; X-ray; Ultrasound; CT Scan
• Subsegments:
• 1) By Monoclonal Antibodies: Checkpoint Inhibitors; Targeted Monoclonal Antibodies; Conjugated Antibodies
• 2) By Small Molecule Inhibitors: BRAF Inhibitors; MEK Inhibitors; Other Kinase Inhibitors
• 3) By Other Drug Types: Chemotherapy Agents; Immunotherapy Agents; Adjuvant Therapies
• Companies Mentioned: AstraZeneca plc; Eli Lilly and Company; Merck & Co. Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Bristol-Myers Squibb Company; Oncolys BioPharma Inc.; Iovance Biotherapeutics Inc.; Eisai Co. Ltd.; Seattle Genetics Inc.; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company Limited; Nektar Therapeutics; Immutep Ltd.; Partner Therapeutics Inc.; Infinity Pharmaceuticals Inc.; Spring Bank Pharmaceuticals Inc.; AIM ImmunoTech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Melanoma Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Melanoma Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Melanoma Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Melanoma Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Melanoma Therapy Development
  • 4.2.2 Immunotherapy Adoption Growth
  • 4.2.3 Targeted Therapy Innovation
  • 4.2.4 Advanced Diagnostic Techniques Integration
  • 4.2.5 Combination Treatment Strategies

5. Melanoma Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Research Laboratories
• 5.4 Diagnostic Centers
• 5.5 Pharmaceutical Companies

6. Melanoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Melanoma Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Melanoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Melanoma Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Melanoma Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Melanoma Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Melanoma Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Melanoma Therapeutics Market Segmentation

• 9.1. Global Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types
• 9.2. Global Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgery, Radiation Therapy, Immunotherapy, Targeted Therapy, Chemotherapy
• 9.3. Global Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.4. Global Melanoma Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Superficial Spreading Melanoma, Nodular Melanoma, Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Amelanotic Melanoma, Other Cancer Types
• 9.5. Global Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dermatoscopy, Sentinel Lymph Node Biopsy, Blood Test, X-ray, Ultrasound, CT Scan
• 9.6. Global Melanoma Therapeutics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Checkpoint Inhibitors, Targeted Monoclonal Antibodies, Conjugated Antibodies
• 9.7. Global Melanoma Therapeutics Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• BRAF Inhibitors, MEK Inhibitors, Other Kinase Inhibitors
• 9.8. Global Melanoma Therapeutics Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy Agents, Immunotherapy Agents, Adjuvant Therapies

10. Melanoma Therapeutics Market Regional And Country Analysis

• 10.1. Global Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Melanoma Therapeutics Market

• 11.1. Asia-Pacific Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Melanoma Therapeutics Market

• 12.1. China Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Melanoma Therapeutics Market

• 13.1. India Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Melanoma Therapeutics Market

• 14.1. Japan Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Melanoma Therapeutics Market

• 15.1. Australia Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Melanoma Therapeutics Market

• 16.1. Indonesia Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Melanoma Therapeutics Market

• 17.1. South Korea Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Melanoma Therapeutics Market

• 18.1. Taiwan Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Melanoma Therapeutics Market

• 19.1. South East Asia Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Melanoma Therapeutics Market

• 20.1. Western Europe Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Melanoma Therapeutics Market

• 21.1. UK Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Melanoma Therapeutics Market

• 22.1. Germany Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Melanoma Therapeutics Market

• 23.1. France Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Melanoma Therapeutics Market

• 24.1. Italy Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Melanoma Therapeutics Market

• 25.1. Spain Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Melanoma Therapeutics Market

• 26.1. Eastern Europe Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Melanoma Therapeutics Market

• 27.1. Russia Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Melanoma Therapeutics Market

• 28.1. North America Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Melanoma Therapeutics Market

• 29.1. USA Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Melanoma Therapeutics Market

• 30.1. Canada Melanoma Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Melanoma Therapeutics Market

• 31.1. South America Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Melanoma Therapeutics Market

• 32.1. Brazil Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Melanoma Therapeutics Market

• 33.1. Middle East Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Melanoma Therapeutics Market

• 34.1. Africa Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Melanoma Therapeutics Market, Segmentation By Drug Type, Segmentation By Therapy, Segmentation By Route of administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Melanoma Therapeutics Market Regulatory and Investment Landscape

36. Melanoma Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Melanoma Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Melanoma Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Melanoma Therapeutics Market Company Profiles
  • 36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Melanoma Therapeutics Market Other Major And Innovative Companies

• F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, Oncolys BioPharma Inc., Iovance Biotherapeutics Inc., Eisai Co. Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics Inc., Infinity Pharmaceuticals Inc., Spring Bank Pharmaceuticals Inc.

38. Global Melanoma Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Melanoma Therapeutics Market

40. Melanoma Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Melanoma Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Melanoma Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Melanoma Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer